Pet Cancer Therapeutics Market By Animal Type (Dogs, Cats, Horses, Others); By Cancer Type (Mast Cell Cancer, Lymphoma, Melanoma, Mammary, Squamous Cell Cancer, Others); By Route of Administration (Oral, Intravenous, Others); By Therapy Type (Chemotherapy, Targeted Therapy, Combination Therapy, Immunotherapy); By Region (U.S., Canada, Mexico Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, The Benelux Union, Rest of Europe, China, Japan, India, Australia, New Zealand, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 – 2027
Industry Trends
Rising prevalence of cancer among the cats and dogs is expected to propel the overall industry growth. The Veterinary Cancer Society reported that cancer is the leading cause of death for 47.5% of the dogs who are aged over ten and 32% of the cats. The most common cancer type among the dogs are different forms of lymphoma, showing enlargement of external lymph nodes. Early detection and adequate treatment are the best way to manage cancer in pets. Most prevalent types of cancer occurs in skin, mammary gland, head & neck, testicles, abdominal cancer and bone. Cancer treatment types include surgery, chemotherapy, stereotactic radiation, conventional radiation therapy, palliative care, immunotherapy, cryotherapy and radioactive iodine I-131. Increasing investment for research and development for new diagnostic methods and treatments for cancer management will drive the growth of pet cancer therapeutics market.
Pharmaceutical companies investing in veterinary medicine have introduced a robust pipeline of drug for the treatment of highly prevalent conditions in pets such as lymphoma and melanoma. In January 2018, Aratana Therapeutics announced approval of its canine osteosarcoma vaccine, Live Listeria Vector (AT-014), from United States Department of Agriculture (USDA) Center. Private and government organizations such as Veterinary Cancer Society, Petco Foundation and Animal Cancer foundation are also working together with pharmaceutical companies to formulate novel drug for pet cancer therapeutics which will positively impact the industry growth.
Spotlight Innovation, Inc., announced that it has formed a subsidiary named, CDT Veterinary Therapeutics, Inc., to develop cancer therapeutics for the veterinary market. The company is a third subsidiary of Spotlight Innovation's along with Memcine Pharmaceuticals and Celtic Biotech. The company commercialized the production of Crotalin which is considered an effective cancer therapeutic in companion animals. According to the American Veterinary Medical Association (AAPA), veterinary care costs were approximately US$15.04 billion in the United States for the year 2014. Due to increasing costs, the North American Pet Health Insurance Association duly reported the increased companion animal healthcare insurance policies since 2009. Increasing number of such policies since then and addition of the same in the year 2013, has estimated the North America market size to be US$ 601.43 million in in 2014.
North America Pet Cancer Therapeutics Market Sales, 2019 - 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of global pet cancer therapeutics market, as well as provides worthy insights into the rational scenario and favored development methods adopted by key contenders. The report also offers extensive research on the key players in global diesel engine and gas engine market and detailed insights on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their headquarter, competitors, product/service type, application and specification, pricing, and gross margin.
The Pet Cancer Therapeutics market participants in global diesel engine and gas engine market include AdvaVet, Advaxis Inc., Amgen Inc., Aratana Therapeutics, Inc., Boehringer Ingelheim International GmbH, CanFel Therapeutics, ELIAS Animal Health, Fetch Pharma, Genentech, Innogenics, Karyopharm Therapeutics, Kindred Biosciences, Morphogenesis, Inc., NIPPON ZENYAKU KOGYO CO., LTD., Oasmia Pharmaceutical AB, PetLife Pharmaceuticals, Inc., Pharmaust., Phibro Animal Health Corporation, Regeneus Ltd, Rhizen Pharmaceuticals S.A., Torigen Pharmaceutical Inc., Vaccibody, VetDC, Virbac., Zoetis Services LLC amongst others.
By Animal Type
- Dogs
- Cats
- Horses
- Others
By Cancer Type
- Mast Cell Cancer
- Lymphoma
- Melanoma
- Mammary
- Squamous Cell Cancer
- Others
By Route of Administration
- Oral
- Intravenous
- Others
By Therapy Type
- Chemotherapy
- Targeted Therapy
- Combination Therapy
- Immunotherapy
By Geography
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
1. Introduction
1.1.
Market Scope
1.2. Years Considered
1.2.1. Historic Years: 2013 - 2017
1.2.2. Base Year: 2018
1.2.3. Forecast Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Country-Wise Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Pet Cancer Therapeutics Market
6. Market Synopsis: Pet
Cancer Therapeutics Market
7. Pet Cancer Therapeutics Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4.
Challenges
7.3.
Trends in Pet Cancer Therapeutics Market
7.4.
Market Determinants Radar
Chart
7.5.
Porter’s Five Force
Analysis
7.6. Pricing Analysis, By Region (2017 and 2018)
7.6.1. North America
7.6.1.1. U.S
7.6.1.2. Canada
7.6.1.3. Mexico
7.6.2. Europe
7.6.2.1. France
7.6.2.2. The UK
7.6.2.3. Spain
7.6.2.4. Germany
7.6.2.5.
Italy
7.6.2.6.
Denmark
7.6.2.7.
Finland
7.6.2.8.
Iceland
7.6.2.9.
Norway
7.6.2.10.
Sweden
7.6.2.11.
Russia
7.6.2.12.
Belgium
7.6.2.13.
The Netherlands
7.6.2.14.
Luxembourg
7.6.3. Asia Pacific
7.6.3.1. China
7.6.3.2. Japan
7.6.3.3. India
7.6.3.4.
New Zealand
7.6.3.5.
Malaysia
7.6.3.6.
Taiwan
7.6.3.7.
Russia
7.6.3.8.
Singapore
7.6.3.9. Hong Kong
7.6.3.10. Australia
7.6.3.11. Southeast Asia
7.6.4. Middle East and Africa
7.6.4.1.
GCC Countries
7.6.4.2.
UAE
7.6.4.3. Saudi Arabia
7.6.4.4. Southern Africa
7.6.5. Latin America
7.6.5.1.
Brazil
7.6.5.2. Argentina
8. Global Pet Cancer Therapeutics Market Analysis and Forecasts,
2019 – 2027
8.1. Overview
8.1.1. Global Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts
8.2. Global Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Animal Type
8.2.1. Dogs
8.2.1.1. Definition
8.2.1.2. Market Penetration, 2018
8.2.1.3. Market Estimation, 2013 – 2018
8.2.1.4. Market Forecast, 2019 – 2027
8.2.1.5. Compound Annual Growth Rate (CAGR)
8.2.1.6. Regional Bifurcation
8.2.1.6.1. North America
8.2.1.6.1.1. Market Estimation, 2013 – 2018
8.2.1.6.1.2. Market Forecast, 2019 – 2027
8.2.1.6.2. Europe
8.2.1.6.2.1. Market Estimation, 2013 – 2018
8.2.1.6.2.2. Market Forecast, 2019 – 2027
8.2.1.6.3. Asia Pacific
8.2.1.6.3.1. Market Estimation, 2013 – 2018
8.2.1.6.3.2. Market Forecast, 2019 – 2027
8.2.1.6.4. Middle East and Africa
8.2.1.6.4.1. Market Estimation, 2013 – 2018
8.2.1.6.4.2. Market Forecast, 2019 – 2027
8.2.1.6.5. Latin America
8.2.1.6.5.1. Market Estimation, 2013 – 2018
8.2.1.6.5.2.
Market Forecast, 2019 –
2027
8.2.2. Cats
8.2.2.1. Definition
8.2.2.2. Market Penetration, 2018
8.2.2.3. Market Estimation, 2013 – 2018
8.2.2.4. Market Forecast, 2019 – 2027
8.2.2.5. Compound Annual Growth Rate (CAGR)
8.2.2.6. Regional Bifurcation
8.2.2.6.1. North America
8.2.2.6.1.1. Market Estimation, 2013 – 2018
8.2.2.6.1.2. Market Forecast, 2019 – 2027
8.2.2.6.2. Europe
8.2.2.6.2.1. Market Estimation, 2013 – 2018
8.2.2.6.2.2. Market Forecast, 2019 – 2027
8.2.2.6.3. Asia Pacific
8.2.2.6.3.1. Market Estimation, 2013 – 2018
8.2.2.6.3.2. Market Forecast, 2019 – 2027
8.2.2.6.4. Middle East and Africa
8.2.2.6.4.1. Market Estimation, 2013 – 2018
8.2.2.6.4.2. Market Forecast, 2019 – 2027
8.2.2.6.5. Latin America
8.2.2.6.5.1. Market Estimation, 2013 – 2018
8.2.2.6.5.2.
Market Forecast, 2019 –
2027
8.2.3. Horses
8.2.3.1. Definition
8.2.3.2. Market Penetration, 2018
8.2.3.3. Market Estimation, 2013 – 2018
8.2.3.4. Market Forecast, 2019 – 2027
8.2.3.5. Compound Annual Growth Rate (CAGR)
8.2.3.6. Regional Bifurcation
8.2.3.6.1. North America
8.2.3.6.1.1. Market Estimation, 2013 – 2018
8.2.3.6.1.2. Market Forecast, 2019 – 2027
8.2.3.6.2. Europe
8.2.3.6.2.1. Market Estimation, 2013 – 2018
8.2.3.6.2.2. Market Forecast, 2019 – 2027
8.2.3.6.3. Asia Pacific
8.2.3.6.3.1. Market Estimation, 2013 – 2018
8.2.3.6.3.2. Market Forecast, 2019 – 2027
8.2.3.6.4. Middle East and Africa
8.2.3.6.4.1. Market Estimation, 2013 – 2018
8.2.3.6.4.2. Market Forecast, 2019 – 2027
8.2.3.6.5. Latin America
8.2.3.6.5.1. Market Estimation, 2013 – 2018
8.2.3.6.5.2.
Market Forecast, 2019 –
2027
8.2.4. Others
8.2.4.1. Definition
8.2.4.2. Market Penetration, 2018
8.2.4.3. Market Estimation, 2013 – 2018
8.2.4.4. Market Forecast, 2019 – 2027
8.2.4.5. Compound Annual Growth Rate (CAGR)
8.2.4.6. Regional Bifurcation
8.2.4.6.1. North America
8.2.4.6.1.1. Market Estimation, 2013 – 2018
8.2.4.6.1.2. Market Forecast, 2019 – 2027
8.2.4.6.2. Europe
8.2.4.6.2.1. Market Estimation, 2013 – 2018
8.2.4.6.2.2. Market Forecast, 2019 – 2027
8.2.4.6.3. Asia Pacific
8.2.4.6.3.1. Market Estimation, 2013 – 2018
8.2.4.6.3.2. Market Forecast, 2019 – 2027
8.2.4.6.4. Middle East and Africa
8.2.4.6.4.1. Market Estimation, 2013 – 2018
8.2.4.6.4.2. Market Forecast, 2019 – 2027
8.2.4.6.5. Latin America
8.2.4.6.5.1. Market Estimation, 2013 – 2018
8.2.4.6.5.2.
Market Forecast, 2019 –
2027
8.3. Key Segment for Channeling Investments
8.3.1. By Animal Type
9. Global Pet Cancer Therapeutics Market Analysis and Forecasts,
2019 – 2027
9.1. Overview
9.2. Global Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Cancer Type
9.2.1. Mast Cell Cancer
9.2.1.1. Definition
9.2.1.2. Market Penetration, 2018
9.2.1.3. Market Estimation, 2013 – 2018
9.2.1.4. Market Forecast, 2019 – 2027
9.2.1.5. Compound Annual Growth Rate (CAGR)
9.2.1.6. Regional Bifurcation
9.2.1.6.1. North America
9.2.1.6.1.1. Market Estimation, 2013 – 2018
9.2.1.6.1.2. Market Forecast, 2019 – 2027
9.2.1.6.2. Europe
9.2.1.6.2.1. Market Estimation, 2013 – 2018
9.2.1.6.2.2. Market Forecast, 2019 – 2027
9.2.1.6.3. Asia Pacific
9.2.1.6.3.1. Market Estimation, 2013 – 2018
9.2.1.6.3.2. Market Forecast, 2019 – 2027
9.2.1.6.4. Middle East and Africa
9.2.1.6.4.1. Market Estimation, 2013 – 2018
9.2.1.6.4.2. Market Forecast, 2019 – 2027
9.2.1.6.5. Latin America
9.2.1.6.5.1. Market Estimation, 2013 – 2018
9.2.1.6.5.2.
Market Forecast, 2019 –
2027
9.2.2. Lymphoma
9.2.2.1. Definition
9.2.2.2. Market Penetration, 2018
9.2.2.3. Market Estimation, 2013 – 2018
9.2.2.4. Market Forecast, 2019 – 2027
9.2.2.5. Compound Annual Growth Rate (CAGR)
9.2.2.6. Regional Bifurcation
9.2.2.6.1. North America
9.2.2.6.1.1. Market Estimation, 2013 – 2018
9.2.2.6.1.2. Market Forecast, 2019 – 2027
9.2.2.6.2. Europe
9.2.2.6.2.1. Market Estimation, 2013 – 2018
9.2.2.6.2.2. Market Forecast, 2019 – 2027
9.2.2.6.3. Asia Pacific
9.2.2.6.3.1. Market Estimation, 2013 – 2018
9.2.2.6.3.2. Market Forecast, 2019 – 2027
9.2.2.6.4. Middle East and Africa
9.2.2.6.4.1. Market Estimation, 2013 – 2018
9.2.2.6.4.2. Market Forecast, 2019 – 2027
9.2.2.6.5. Latin America
9.2.2.6.5.1. Market Estimation, 2013 – 2018
9.2.2.6.5.2. Market Forecast, 2019 – 2027
9.2.3. Melanoma
9.2.3.1. Definition
9.2.3.2. Market Penetration, 2018
9.2.3.3. Market Estimation, 2013 – 2018
9.2.3.4. Market Forecast, 2019 – 2027
9.2.3.5. Compound Annual Growth Rate (CAGR)
9.2.3.6. Regional Bifurcation
9.2.3.6.1. North America
9.2.3.6.1.1. Market Estimation, 2013 – 2018
9.2.3.6.1.2. Market Forecast, 2019 – 2027
9.2.3.6.2. Europe
9.2.3.6.2.1. Market Estimation, 2013 – 2018
9.2.3.6.2.2. Market Forecast, 2019 – 2027
9.2.3.6.3. Asia Pacific
9.2.3.6.3.1. Market Estimation, 2013 – 2018
9.2.3.6.3.2. Market Forecast, 2019 – 2027
9.2.3.6.4. Middle East and Africa
9.2.3.6.4.1. Market Estimation, 2013 – 2018
9.2.3.6.4.2. Market Forecast, 2019 – 2027
9.2.3.6.5. Latin America
9.2.3.6.5.1. Market Estimation, 2013 – 2018
9.2.3.6.5.2. Market Forecast, 2019 – 2027
9.2.4. Mammary
9.2.4.1. Definition
9.2.4.2. Market Penetration, 2018
9.2.4.3. Market Estimation, 2013 – 2018
9.2.4.4. Market Forecast, 2019 – 2027
9.2.4.5. Compound Annual Growth Rate (CAGR)
9.2.4.6. Regional Bifurcation
9.2.4.6.1. North America
9.2.4.6.1.1. Market Estimation, 2013 – 2018
9.2.4.6.1.2. Market Forecast, 2019 – 2027
9.2.4.6.2. Europe
9.2.4.6.2.1. Market Estimation, 2013 – 2018
9.2.4.6.2.2. Market Forecast, 2019 – 2027
9.2.4.6.3. Asia Pacific
9.2.4.6.3.1. Market Estimation, 2013 – 2018
9.2.4.6.3.2. Market Forecast, 2019 – 2027
9.2.4.6.4. Middle East and Africa
9.2.4.6.4.1. Market Estimation, 2013 – 2018
9.2.4.6.4.2. Market Forecast, 2019 – 2027
9.2.4.6.5. Latin America
9.2.4.6.5.1. Market Estimation, 2013 – 2018
9.2.4.6.5.2. Market Forecast, 2019 – 2027
9.2.5. Squamous Cell Cancer
9.2.5.1. Definition
9.2.5.2. Market Penetration, 2018
9.2.5.3. Market Estimation, 2013 – 2018
9.2.5.4. Market Forecast, 2019 – 2027
9.2.5.5. Compound Annual Growth Rate (CAGR)
9.2.5.6. Regional Bifurcation
9.2.5.6.1. North America
9.2.5.6.1.1. Market Estimation, 2013 – 2018
9.2.5.6.1.2. Market Forecast, 2019 – 2027
9.2.5.6.2. Europe
9.2.5.6.2.1. Market Estimation, 2013 – 2018
9.2.5.6.2.2. Market Forecast, 2019 – 2027
9.2.5.6.3. Asia Pacific
9.2.5.6.3.1. Market Estimation, 2013 – 2018
9.2.5.6.3.2. Market Forecast, 2019 – 2027
9.2.5.6.4. Middle East and Africa
9.2.5.6.4.1. Market Estimation, 2013 – 2018
9.2.5.6.4.2. Market Forecast, 2019 – 2027
9.2.5.6.5. Latin America
9.2.5.6.5.1. Market Estimation, 2013 – 2018
9.2.5.6.5.2. Market Forecast, 2019 – 2027
9.2.6. Others
9.2.6.1. Definition
9.2.6.2. Market Penetration, 2018
9.2.6.3. Market Estimation, 2013 – 2018
9.2.6.4. Market Forecast, 2019 – 2027
9.2.6.5. Compound Annual Growth Rate (CAGR)
9.2.6.6. Regional Bifurcation
9.2.6.6.1. North America
9.2.6.6.1.1. Market Estimation, 2013 – 2018
9.2.6.6.1.2. Market Forecast, 2019 – 2027
9.2.6.6.2. Europe
9.2.6.6.2.1. Market Estimation, 2013 – 2018
9.2.6.6.2.2. Market Forecast, 2019 – 2027
9.2.6.6.3. Asia Pacific
9.2.6.6.3.1. Market Estimation, 2013 – 2018
9.2.6.6.3.2. Market Forecast, 2019 – 2027
9.2.6.6.4. Middle East and Africa
9.2.6.6.4.1. Market Estimation, 2013 – 2018
9.2.6.6.4.2. Market Forecast, 2019 – 2027
9.2.6.6.5. Latin America
9.2.6.6.5.1. Market Estimation, 2013 – 2018
9.2.6.6.5.2. Market Forecast, 2019 – 2027
9.3. Key Segment for Channeling Investments
9.3.1. By Cancer Type
10. Global Pet Cancer Therapeutics Market Analysis and Forecasts,
2019 – 2027
10.1. Overview
10.2. Global Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Route of Administration
10.2.1. Oral
10.2.1.1. Definition
10.2.1.2. Market Penetration, 2018
10.2.1.3. Market Estimation, 2013 – 2018
10.2.1.4. Market Forecast, 2019 – 2027
10.2.1.5. Compound Annual Growth Rate (CAGR)
10.2.1.6. Regional Bifurcation
10.2.1.6.1. North America
10.2.1.6.1.1. Market Estimation, 2013 – 2018
10.2.1.6.1.2. Market Forecast, 2019 – 2027
10.2.1.6.2. Europe
10.2.1.6.2.1. Market Estimation, 2013 – 2018
10.2.1.6.2.2. Market
Forecast, 2019 – 2027
10.2.1.6.3. Asia Pacific
10.2.1.6.3.1. Market Estimation, 2013 – 2018
10.2.1.6.3.2. Market Forecast, 2019 – 2027
10.2.1.6.4. Middle East and Africa
10.2.1.6.4.1. Market Estimation, 2013 – 2018
10.2.1.6.4.2. Market Forecast, 2019 – 2027
10.2.1.6.5. Latin America
10.2.1.6.5.1. Market
Estimation, 2013 – 2018
10.2.1.6.5.2. Market
Forecast, 2019 – 2027
10.2.2. Intravenous
10.2.2.1. Definition
10.2.2.2. Market Penetration, 2018
10.2.2.3. Market Estimation, 2013 – 2018
10.2.2.4. Market Forecast, 2019 – 2027
10.2.2.5. Compound Annual Growth Rate (CAGR)
10.2.2.6. Regional Bifurcation
10.2.2.6.1. North America
10.2.2.6.1.1. Market
Estimation, 2013 – 2018
10.2.2.6.1.2. Market
Forecast, 2019 – 2027
10.2.2.6.2. Europe
10.2.2.6.2.1. Market
Estimation, 2013 – 2018
10.2.2.6.2.2. Market
Forecast, 2019 – 2027
10.2.2.6.3. Asia Pacific
10.2.2.6.3.1. Market
Estimation, 2013 – 2018
10.2.2.6.3.2. Market
Forecast, 2019 – 2027
10.2.2.6.4. Middle East and Africa
10.2.2.6.4.1. Market
Estimation, 2013 – 2018
10.2.2.6.4.2. Market
Forecast, 2019 – 2027
10.2.2.6.5. Latin America
10.2.2.6.5.1. Market
Estimation, 2013 – 2018
10.2.2.6.5.2. Market
Forecast, 2019 – 2027
10.2.3. Others
10.2.3.1. Definition
10.2.3.2. Market Penetration, 2018
10.2.3.3. Market Estimation, 2013 – 2018
10.2.3.4. Market Forecast, 2019 – 2027
10.2.3.5. Compound Annual Growth Rate (CAGR)
10.2.3.6. Regional Bifurcation
10.2.3.6.1. North America
10.2.3.6.1.1. Market
Estimation, 2013 – 2018
10.2.3.6.1.2. Market
Forecast, 2019 – 2027
10.2.3.6.2. Europe
10.2.3.6.2.1. Market
Estimation, 2013 – 2018
10.2.3.6.2.2. Market
Forecast, 2019 – 2027
10.2.3.6.3. Asia Pacific
10.2.3.6.3.1. Market
Estimation, 2013 – 2018
10.2.3.6.3.2. Market
Forecast, 2019 – 2027
10.2.3.6.4. Middle East and Africa
10.2.3.6.4.1. Market
Estimation, 2013 – 2018
10.2.3.6.4.2. Market
Forecast, 2019 – 2027
10.2.3.6.5. Latin America
10.2.3.6.5.1. Market
Estimation, 2013 – 2018
10.2.3.6.5.2. Market
Forecast, 2019 – 2027
10.3. Key Segment for Channeling Investments
10.3.1. By Route of Administration
11. Global Pet Cancer Therapeutics Market Analysis and Forecasts,
2019 – 2027
11.1. Overview
11.2. Global Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Therapy Type
11.2.1. Chemotherapy
11.2.1.1. Definition
11.2.1.2. Market Penetration, 2018
11.2.1.3. Market Estimation, 2013 – 2018
11.2.1.4. Market Forecast, 2019 – 2027
11.2.1.5. Compound Annual Growth Rate (CAGR)
11.2.1.6. Regional Bifurcation
11.2.1.6.1. North America
11.2.1.6.1.1. Market
Estimation, 2013 – 2018
11.2.1.6.1.2. Market
Forecast, 2019 – 2027
11.2.1.6.2. Europe
11.2.1.6.2.1. Market
Estimation, 2013 – 2018
11.2.1.6.2.2. Market
Forecast, 2019 – 2027
11.2.1.6.3. Asia Pacific
11.2.1.6.3.1. Market
Estimation, 2013 – 2018
11.2.1.6.3.2. Market
Forecast, 2019 – 2027
11.2.1.6.4. Middle East and Africa
11.2.1.6.4.1. Market
Estimation, 2013 – 2018
11.2.1.6.4.2. Market
Forecast, 2019 – 2027
11.2.1.6.5. Latin America
11.2.1.6.5.1. Market
Estimation, 2013 – 2018
11.2.1.6.5.2. Market
Forecast, 2019 – 2027
11.2.2. Targeted Therapy
11.2.2.1. Definition
11.2.2.2. Market Penetration, 2018
11.2.2.3. Market Estimation, 2013 – 2018
11.2.2.4. Market Forecast, 2019 – 2027
11.2.2.5. Compound Annual Growth Rate (CAGR)
11.2.2.6. Regional Bifurcation
11.2.2.6.1. North America
11.2.2.6.1.1. Market
Estimation, 2013 – 2018
11.2.2.6.1.2. Market
Forecast, 2019 – 2027
11.2.2.6.2. Europe
11.2.2.6.2.1. Market
Estimation, 2013 – 2018
11.2.2.6.2.2. Market
Forecast, 2019 – 2027
11.2.2.6.3. Asia Pacific
11.2.2.6.3.1. Market
Estimation, 2013 – 2018
11.2.2.6.3.2. Market
Forecast, 2019 – 2027
11.2.2.6.4. Middle East and Africa
11.2.2.6.4.1. Market
Estimation, 2013 – 2018
11.2.2.6.4.2. Market
Forecast, 2019 – 2027
11.2.2.6.5. Latin America
11.2.2.6.5.1. Market
Estimation, 2013 – 2018
11.2.2.6.5.2. Market
Forecast, 2019 – 2027
11.2.3. Combination Therapy
11.2.3.1. Definition
11.2.3.2. Market Penetration, 2018
11.2.3.3. Market Estimation, 2013 – 2018
11.2.3.4. Market Forecast, 2019 – 2027
11.2.3.5. Compound Annual Growth Rate (CAGR)
11.2.3.6. Regional Bifurcation
11.2.3.6.1. North America
11.2.3.6.1.1. Market
Estimation, 2013 – 2018
11.2.3.6.1.2. Market
Forecast, 2019 – 2027
11.2.3.6.2. Europe
11.2.3.6.2.1. Market
Estimation, 2013 – 2018
11.2.3.6.2.2. Market
Forecast, 2019 – 2027
11.2.3.6.3. Asia Pacific
11.2.3.6.3.1. Market
Estimation, 2013 – 2018
11.2.3.6.3.2. Market
Forecast, 2019 – 2027
11.2.3.6.4. Middle East and Africa
11.2.3.6.4.1. Market
Estimation, 2013 – 2018
11.2.3.6.4.2. Market
Forecast, 2019 – 2027
11.2.3.6.5. Latin America
11.2.3.6.5.1. Market
Estimation, 2013 – 2018
11.2.3.6.5.2. Market
Forecast, 2019 – 2027
11.2.4. Immunotherapy
11.2.4.1. Definition
11.2.4.2. Market Penetration, 2018
11.2.4.3. Market Estimation, 2013 – 2018
11.2.4.4. Market Forecast, 2019 – 2027
11.2.4.5. Compound Annual Growth Rate (CAGR)
11.2.4.6. Regional Bifurcation
11.2.4.6.1. North America
11.2.4.6.1.1. Market
Estimation, 2013 – 2018
11.2.4.6.1.2. Market
Forecast, 2019 – 2027
11.2.4.6.2. Europe
11.2.4.6.2.1. Market
Estimation, 2013 – 2018
11.2.4.6.2.2. Market
Forecast, 2019 – 2027
11.2.4.6.3. Asia Pacific
11.2.4.6.3.1. Market
Estimation, 2013 – 2018
11.2.4.6.3.2. Market
Forecast, 2019 – 2027
11.2.4.6.4. Middle East and Africa
11.2.4.6.4.1. Market
Estimation, 2013 – 2018
11.2.4.6.4.2. Market
Forecast, 2019 – 2027
11.2.4.6.5. Latin America
11.2.4.6.5.1. Market
Estimation, 2013 – 2018
11.2.4.6.5.2. Market
Forecast, 2019 – 2027
11.3. Key Segment for Channeling Investments
11.3.1. By Therapy Type
12. North America Pet Cancer Therapeutics Market Analysis and
Forecasts, 2019 – 2027
12.1. Overview
12.1.1. North America Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units)
12.2. North America Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Animal Type
12.2.1. Dogs
12.2.2. Cats
12.2.3. Horses
12.2.4. Others
12.3. North America Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Cancer Type
12.3.1. Mast Cell Cancer
12.3.2. Lymphoma
12.3.3. Melanoma
12.3.4. Mammary
12.3.5. Squamous Cell Cancer
12.3.6. Others
12.4. North America Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Route of Administration
12.4.1. Oral
12.4.2. Intravenous
12.4.3. Others
12.5. North America Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Therapy Type
12.5.1. Chemotherapy
12.5.2. Targeted Therapy
12.5.3. Combination Therapy
12.5.4. Immunotherapy
12.6. North America Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Country
12.6.1. U.S.
12.6.1.1. U.S. Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn
and Units) and Forecasts, By Animal Type
12.6.1.1.1. Dogs
12.6.1.1.2. Cats
12.6.1.1.3. Horses
12.6.1.1.4. Others
12.6.1.2. U.S. Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn
and Units) and Forecasts, By Cancer Type
12.6.1.2.1. Mast Cell Cancer
12.6.1.2.2. Lymphoma
12.6.1.2.3. Melanoma
12.6.1.2.4. Mammary
12.6.1.2.5. Squamous Cell Cancer
12.6.1.2.6. Others
12.6.1.3. U.S. Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn
and Units) and Forecasts, By Route of Administration
12.6.1.3.1. Oral
12.6.1.3.2. Intravenous
12.6.1.3.3. Others
12.6.1.4. U.S. Pet Cancer Therapeutics Market Volume and Revenue (US$ Mn
and Units) and Forecasts, By Therapy Type
12.6.1.4.1. Chemotherapy
12.6.1.4.2. Targeted Therapy
12.6.1.4.3. Combination Therapy
12.6.1.4.4.
Immunotherapy
12.6.2. Canada
12.6.2.1. Canada Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Animal Type
12.6.2.1.1. Dogs
12.6.2.1.2. Cats
12.6.2.1.3. Horses
12.6.2.1.4. Others
12.6.2.2. Canada Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Cancer Type
12.6.2.2.1. Mast Cell Cancer
12.6.2.2.2. Lymphoma
12.6.2.2.3. Melanoma
12.6.2.2.4. Mammary
12.6.2.2.5. Squamous Cell Cancer
12.6.2.2.6. Others
12.6.2.3. Canada Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Route of Administration
12.6.2.3.1. Oral
12.6.2.3.2. Intravenous
12.6.2.3.3. Others
12.6.2.4. Canada Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Therapy Type
12.6.2.4.1. Chemotherapy
12.6.2.4.2. Targeted Therapy
12.6.2.4.3. Combination Therapy
12.6.2.4.4.
Immunotherapy
12.6.3. Mexico
12.6.3.1. Mexico Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Animal Type
12.6.3.1.1. Dogs
12.6.3.1.2. Cats
12.6.3.1.3. Horses
12.6.3.1.4. Others
12.6.3.2. Mexico Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Cancer Type
12.6.3.2.1. Mast Cell Cancer
12.6.3.2.2. Lymphoma
12.6.3.2.3. Melanoma
12.6.3.2.4. Mammary
12.6.3.2.5. Squamous Cell Cancer
12.6.3.2.6. Others
12.6.3.3. Mexico Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Route of Administration
12.6.3.3.1. Oral
12.6.3.3.2. Intravenous
12.6.3.3.3. Others
12.6.3.4. Mexico Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Therapy Type
12.6.3.4.1. Chemotherapy
12.6.3.4.2. Targeted Therapy
12.6.3.4.3. Combination Therapy
12.6.3.4.4. Immunotherapy
12.6.4. Rest of North America
12.6.4.1. Rest of North America Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units) and Forecasts, By Animal Type
12.6.4.1.1. Dogs
12.6.4.1.2. Cats
12.6.4.1.3. Horses
12.6.4.1.4. Others
12.6.4.2. Rest of North America Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type
12.6.4.2.1. Mast Cell Cancer
12.6.4.2.2. Lymphoma
12.6.4.2.3. Melanoma
12.6.4.2.4. Mammary
12.6.4.2.5. Squamous Cell Cancer
12.6.4.2.6. Others
12.6.4.3. Rest of North America Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration
12.6.4.3.1. Oral
12.6.4.3.2. Intravenous
12.6.4.3.3. Others
12.6.4.4. Rest of North America Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type
12.6.4.4.1. Chemotherapy
12.6.4.4.2. Targeted Therapy
12.6.4.4.3. Combination Therapy
12.6.4.4.4. Immunotherapy
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Animal Type
12.7.3. By Cancer Type
12.7.4. By Route of Administration
12.7.5. By Therapy Type
13. Europe Pet Cancer Therapeutics Market Analysis and Forecasts,
2019 – 2027
13.1. Overview
13.1.1. Europe Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units)
13.2. Europe Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Animal Type
13.2.1. Dogs
13.2.2. Cats
13.2.3. Horses
13.2.4. Others
13.3. Europe Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Cancer Type
13.3.1. Mast Cell Cancer
13.3.2. Lymphoma
13.3.3. Melanoma
13.3.4. Mammary
13.3.5. Squamous Cell Cancer
13.3.6. Others
13.4. Europe Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Route of Administration
13.4.1. Oral
13.4.2. Intravenous
13.4.3. Others
13.5. Europe Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Therapy Type
13.5.1. Chemotherapy
13.5.2. Targeted Therapy
13.5.3. Combination Therapy
13.5.4. Immunotherapy
13.6. Europe Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Animal Type
13.6.1.1.1. Dogs
13.6.1.1.2. Cats
13.6.1.1.3. Horses
13.6.1.1.4. Others
13.6.1.2. France Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Cancer Type
13.6.1.2.1. Mast Cell Cancer
13.6.1.2.2. Lymphoma
13.6.1.2.3. Melanoma
13.6.1.2.4. Mammary
13.6.1.2.5. Squamous Cell Cancer
13.6.1.2.6. Others
13.6.1.3. France Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Route of Administration
13.6.1.3.1. Oral
13.6.1.3.2. Intravenous
13.6.1.3.3. Others
13.6.1.4. France Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Therapy Type
13.6.1.4.1. Chemotherapy
13.6.1.4.2. Targeted Therapy
13.6.1.4.3. Combination Therapy
13.6.1.4.4. Immunotherapy
13.6.2. The UK
13.6.2.1. The UK Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Animal Type
13.6.2.1.1. Dogs
13.6.2.1.2. Cats
13.6.2.1.3. Horses
13.6.2.1.4. Others
13.6.2.2. The UK Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Cancer Type
13.6.2.2.1. Mast Cell Cancer
13.6.2.2.2. Lymphoma
13.6.2.2.3. Melanoma
13.6.2.2.4. Mammary
13.6.2.2.5. Squamous Cell Cancer
13.6.2.2.6. Others
13.6.2.3. The UK Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Route of Administration
13.6.2.3.1. Oral
13.6.2.3.2. Intravenous
13.6.2.3.3. Others
13.6.2.4. The UK Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Therapy Type
13.6.2.4.1. Chemotherapy
13.6.2.4.2. Targeted Therapy
13.6.2.4.3. Combination Therapy
13.6.2.4.4. Immunotherapy
13.6.3. Spain
13.6.3.1. Spain Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Animal Type
13.6.3.1.1. Dogs
13.6.3.1.2. Cats
13.6.3.1.3. Horses
13.6.3.1.4. Others
13.6.3.2. Spain Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Cancer Type
13.6.3.2.1. Mast Cell Cancer
13.6.3.2.2. Lymphoma
13.6.3.2.3. Melanoma
13.6.3.2.4. Mammary
13.6.3.2.5. Squamous Cell Cancer
13.6.3.2.6. Others
13.6.3.3. Spain Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Route of Administration
13.6.3.3.1. Oral
13.6.3.3.2. Intravenous
13.6.3.3.3. Others
13.6.3.4. Spain Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Therapy Type
13.6.3.4.1. Chemotherapy
13.6.3.4.2. Targeted Therapy
13.6.3.4.3. Combination Therapy
13.6.3.4.4. Immunotherapy
13.6.4. Germany
13.6.4.1. Germany Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Animal Type
13.6.4.1.1. Dogs
13.6.4.1.2. Cats
13.6.4.1.3. Horses
13.6.4.1.4. Others
13.6.4.2. Germany Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Cancer Type
13.6.4.2.1. Mast Cell Cancer
13.6.4.2.2. Lymphoma
13.6.4.2.3. Melanoma
13.6.4.2.4. Mammary
13.6.4.2.5. Squamous Cell Cancer
13.6.4.2.6. Others
13.6.4.3. Germany Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Route of Administration
13.6.4.3.1. Oral
13.6.4.3.2. Intravenous
13.6.4.3.3. Others
13.6.4.4. Germany Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Therapy Type
13.6.4.4.1. Chemotherapy
13.6.4.4.2. Targeted Therapy
13.6.4.4.3. Combination Therapy
13.6.4.4.4. Immunotherapy
13.6.5. Italy
13.6.5.1. Italy Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Animal Type
13.6.5.1.1. Dogs
13.6.5.1.2. Cats
13.6.5.1.3. Horses
13.6.5.1.4. Others
13.6.5.2. Italy Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Cancer Type
13.6.5.2.1. Mast Cell Cancer
13.6.5.2.2. Lymphoma
13.6.5.2.3. Melanoma
13.6.5.2.4. Mammary
13.6.5.2.5. Squamous Cell Cancer
13.6.5.2.6. Others
13.6.5.3. Italy Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Route of Administration
13.6.5.3.1. Oral
13.6.5.3.2. Intravenous
13.6.5.3.3. Others
13.6.5.4. Italy Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Therapy Type
13.6.5.4.1. Chemotherapy
13.6.5.4.2. Targeted Therapy
13.6.5.4.3. Combination Therapy
13.6.5.4.4. Immunotherapy
13.6.6. Nordic Countries
13.6.6.1. Nordic Countries Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Animal Type
13.6.6.1.1. Dogs
13.6.6.1.2. Cats
13.6.6.1.3. Horses
13.6.6.1.4. Others
13.6.6.2. Nordic Countries Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Cancer Type
13.6.6.2.1. Mast Cell Cancer
13.6.6.2.2. Lymphoma
13.6.6.2.3. Melanoma
13.6.6.2.4. Mammary
13.6.6.2.5. Squamous Cell Cancer
13.6.6.2.6. Others
13.6.6.3. Nordic Countries Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Route of Administration
13.6.6.3.1. Oral
13.6.6.3.2. Intravenous
13.6.6.3.3. Others
13.6.6.4. Nordic Countries Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Therapy Type
13.6.6.4.1. Chemotherapy
13.6.6.4.2. Targeted Therapy
13.6.6.4.3. Combination Therapy
13.6.6.4.4.
Immunotherapy
13.6.6.5.
Nordic Countries Pet
Cancer Therapeutics Market Volume and Revenue (US$ Mn and Units) and Forecasts,
By Country
13.6.6.5.1.
Finland
13.6.6.5.2.
Denmark
13.6.6.5.3.
Norway
13.6.6.5.4.
Sweden
13.6.6.5.5.
Iceland
13.6.6.5.6.
Rest of Nordic Countries
13.6.7. The Benelux Union
13.6.7.1. The Benelux Union Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Animal Type
13.6.7.1.1. Dogs
13.6.7.1.2. Cats
13.6.7.1.3. Horses
13.6.7.1.4. Others
13.6.7.2. The Benelux Union Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Cancer Type
13.6.7.2.1. Mast Cell Cancer
13.6.7.2.2. Lymphoma
13.6.7.2.3. Melanoma
13.6.7.2.4. Mammary
13.6.7.2.5. Squamous Cell Cancer
13.6.7.2.6. Others
13.6.7.3. The Benelux Union Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Route of Administration
13.6.7.3.1. Oral
13.6.7.3.2. Intravenous
13.6.7.3.3. Others
13.6.7.4. The Benelux Union Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Therapy Type
13.6.7.4.1. Chemotherapy
13.6.7.4.2. Targeted Therapy
13.6.7.4.3. Combination Therapy
13.6.7.4.4. Immunotherapy
13.6.7.5. The Benelux Union Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Therapy Type
13.6.7.5.1. Belgium
13.6.7.5.2. The
Netherlands
13.6.7.5.3. Luxemburg
13.6.8. Rest of Europe
13.6.8.1. Rest of Europe Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Animal Type
13.6.8.1.1. Dogs
13.6.8.1.2. Cats
13.6.8.1.3. Horses
13.6.8.1.4. Others
13.6.8.2. Rest of Europe Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Cancer Type
13.6.8.2.1. Mast Cell Cancer
13.6.8.2.2. Lymphoma
13.6.8.2.3. Melanoma
13.6.8.2.4. Mammary
13.6.8.2.5. Squamous Cell Cancer
13.6.8.2.6. Others
13.6.8.3. Rest of Europe Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Route of Administration
13.6.8.3.1. Oral
13.6.8.3.2. Intravenous
13.6.8.3.3. Others
13.6.8.4. Rest of Europe Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Therapy Type
13.6.8.4.1. Chemotherapy
13.6.8.4.2. Targeted Therapy
13.6.8.4.3. Combination Therapy
13.6.8.4.4. Immunotherapy
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Animal Type
13.7.3. By Cancer Type
13.7.4. By Route of Administration
13.7.5. By Therapy Type
14. Asia Pacific Pet
Cancer Therapeutics Market Analysis and Forecasts, 2019 – 2027
14.1. Overview
14.1.1. Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units)
14.2. Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Animal Type
14.2.1. Dogs
14.2.2. Cats
14.2.3. Horses
14.2.4. Others
14.3. Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Cancer Type
14.3.1. Mast Cell Cancer
14.3.2. Lymphoma
14.3.3. Melanoma
14.3.4. Mammary
14.3.5. Squamous Cell Cancer
14.3.6. Others
14.4. Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Route of Administration
14.4.1. Oral
14.4.2. Intravenous
14.4.3. Others
14.5. Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Therapy Type
14.5.1. Chemotherapy
14.5.2. Targeted Therapy
14.5.3. Combination Therapy
14.5.4. Immunotherapy
14.6. Asia Pacific Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Animal Type
14.6.1.1.1. Dogs
14.6.1.1.2. Cats
14.6.1.1.3. Horses
14.6.1.1.4. Others
14.6.1.2. China Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Cancer Type
14.6.1.2.1. Mast Cell Cancer
14.6.1.2.2. Lymphoma
14.6.1.2.3. Melanoma
14.6.1.2.4. Mammary
14.6.1.2.5. Squamous Cell Cancer
14.6.1.2.6. Others
14.6.1.3. China Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Route of Administration
14.6.1.3.1. Oral
14.6.1.3.2. Intravenous
14.6.1.3.3. Others
14.6.1.4. China Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Therapy Type
14.6.1.4.1. Chemotherapy
14.6.1.4.2. Targeted Therapy
14.6.1.4.3. Combination Therapy
14.6.1.4.4. Immunotherapy
14.6.2. Japan
14.6.2.1. Japan Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Animal Type
14.6.2.1.1. Dogs
14.6.2.1.2. Cats
14.6.2.1.3. Horses
14.6.2.1.4. Others
14.6.2.2. Japan Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Cancer Type
14.6.2.2.1. Mast Cell Cancer
14.6.2.2.2. Lymphoma
14.6.2.2.3. Melanoma
14.6.2.2.4. Mammary
14.6.2.2.5. Squamous Cell Cancer
14.6.2.2.6. Others
14.6.2.3. Japan Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Route of Administration
14.6.2.3.1. Oral
14.6.2.3.2. Intravenous
14.6.2.3.3. Others
14.6.2.4. Japan Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Therapy Type
14.6.2.4.1. Chemotherapy
14.6.2.4.2. Targeted Therapy
14.6.2.4.3. Combination Therapy
14.6.2.4.4. Immunotherapy
14.6.3. India
14.6.3.1. India Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Animal Type
14.6.3.1.1. Dogs
14.6.3.1.2. Cats
14.6.3.1.3. Horses
14.6.3.1.4. Others
14.6.3.2. India Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Cancer Type
14.6.3.2.1. Mast Cell Cancer
14.6.3.2.2. Lymphoma
14.6.3.2.3. Melanoma
14.6.3.2.4. Mammary
14.6.3.2.5. Squamous Cell Cancer
14.6.3.2.6. Others
14.6.3.3. India Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Route of Administration
14.6.3.3.1. Oral
14.6.3.3.2. Intravenous
14.6.3.3.3. Others
14.6.3.4. India Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Therapy Type
14.6.3.4.1. Chemotherapy
14.6.3.4.2. Targeted Therapy
14.6.3.4.3. Combination Therapy
14.6.3.4.4.
Immunotherapy
14.6.4. Australia
14.6.4.1. Australia Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Animal Type
14.6.4.1.1. Dogs
14.6.4.1.2. Cats
14.6.4.1.3. Horses
14.6.4.1.4. Others
14.6.4.2. Australia Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Cancer Type
14.6.4.2.1. Mast Cell Cancer
14.6.4.2.2. Lymphoma
14.6.4.2.3. Melanoma
14.6.4.2.4. Mammary
14.6.4.2.5. Squamous Cell Cancer
14.6.4.2.6. Others
14.6.4.3. Australia Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Route of Administration
14.6.4.3.1. Oral
14.6.4.3.2. Intravenous
14.6.4.3.3. Others
14.6.4.4. Australia Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Therapy Type
14.6.4.4.1. Chemotherapy
14.6.4.4.2. Targeted Therapy
14.6.4.4.3. Combination Therapy
14.6.4.4.4.
Immunotherapy
14.6.5. New Zealand
14.6.5.1. New Zealand Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Animal Type
14.6.5.1.1. Dogs
14.6.5.1.2. Cats
14.6.5.1.3. Horses
14.6.5.1.4. Others
14.6.5.2. New Zealand Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Cancer Type
14.6.5.2.1. Mast Cell Cancer
14.6.5.2.2. Lymphoma
14.6.5.2.3. Melanoma
14.6.5.2.4. Mammary
14.6.5.2.5. Squamous Cell Cancer
14.6.5.2.6. Others
14.6.5.3. New Zealand Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Route of Administration
14.6.5.3.1. Oral
14.6.5.3.2. Intravenous
14.6.5.3.3. Others
14.6.5.4. New Zealand Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Therapy Type
14.6.5.4.1. Chemotherapy
14.6.5.4.2. Targeted Therapy
14.6.5.4.3. Combination Therapy
14.6.5.4.4. Immunotherapy
14.6.6. Southeast Asia
14.6.6.1. Southeast Asia Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Animal Type
14.6.6.1.1. Dogs
14.6.6.1.2. Cats
14.6.6.1.3. Horses
14.6.6.1.4. Others
14.6.6.2. Southeast Asia Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Cancer Type
14.6.6.2.1. Mast Cell Cancer
14.6.6.2.2. Lymphoma
14.6.6.2.3. Melanoma
14.6.6.2.4. Mammary
14.6.6.2.5. Squamous Cell Cancer
14.6.6.2.6. Others
14.6.6.3. Southeast Asia Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Route of Administration
14.6.6.3.1. Oral
14.6.6.3.2. Intravenous
14.6.6.3.3. Others
14.6.6.4. Southeast Asia Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Therapy Type
14.6.6.4.1. Chemotherapy
14.6.6.4.2. Targeted Therapy
14.6.6.4.3. Combination Therapy
14.6.6.4.4. Immunotherapy
14.6.7. Rest of Asia Pacific
14.6.7.1. Rest of Asia Pacific Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Animal Type
14.6.7.1.1. Dogs
14.6.7.1.2. Cats
14.6.7.1.3. Horses
14.6.7.1.4. Others
14.6.7.2. Rest of Asia Pacific Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Cancer Type
14.6.7.2.1. Mast Cell Cancer
14.6.7.2.2. Lymphoma
14.6.7.2.3. Melanoma
14.6.7.2.4. Mammary
14.6.7.2.5. Squamous Cell Cancer
14.6.7.2.6. Others
14.6.7.3. Rest of Asia Pacific Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Route of Administration
14.6.7.3.1. Oral
14.6.7.3.2. Intravenous
14.6.7.3.3. Others
14.6.7.4. Rest of Asia Pacific Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Therapy Type
14.6.7.4.1. Chemotherapy
14.6.7.4.2. Targeted Therapy
14.6.7.4.3. Combination Therapy
14.6.7.4.4. Immunotherapy
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Animal Type
14.7.3. By Cancer Type
14.7.4. By Route of Administration
14.7.5. By Therapy Type
15. Middle East and Africa
Pet Cancer Therapeutics Market Analysis and Forecasts, 2019 – 2027
15.1. Overview
15.1.1. Middle East and Africa Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units)
15.2. Middle East and Africa Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units) and Forecasts, By Animal Type
15.2.1. Dogs
15.2.2. Cats
15.2.3. Horses
15.2.4. Others
15.3. Middle East and Africa Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type
15.3.1. Mast Cell Cancer
15.3.2. Lymphoma
15.3.3. Melanoma
15.3.4. Mammary
15.3.5. Squamous Cell Cancer
15.3.6. Others
15.4. Middle East and Africa Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration
15.4.1. Oral
15.4.2. Intravenous
15.4.3. Others
15.5. Middle East and Africa Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type
15.5.1. Chemotherapy
15.5.2. Targeted Therapy
15.5.3. Combination Therapy
15.5.4. Immunotherapy
15.6. Middle East and Africa Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units) and Forecasts, By Country
15.6.1. GCC Countries
15.6.1.1. GCC Countries Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Animal Type
15.6.1.1.1. Dogs
15.6.1.1.2. Cats
15.6.1.1.3. Horses
15.6.1.1.4. Others
15.6.1.2. GCC Countries Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Cancer Type
15.6.1.2.1. Mast Cell Cancer
15.6.1.2.2. Lymphoma
15.6.1.2.3. Melanoma
15.6.1.2.4. Mammary
15.6.1.2.5. Squamous Cell Cancer
15.6.1.2.6. Others
15.6.1.3. GCC Countries Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Route of Administration
15.6.1.3.1. Oral
15.6.1.3.2. Intravenous
15.6.1.3.3. Others
15.6.1.4. GCC Countries Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Therapy Type
15.6.1.4.1. Chemotherapy
15.6.1.4.2. Targeted Therapy
15.6.1.4.3. Combination Therapy
15.6.1.4.4. Immunotherapy
15.6.2. Southern Africa
15.6.2.1. Southern Africa Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Animal Type
15.6.2.1.1. Dogs
15.6.2.1.2. Cats
15.6.2.1.3. Horses
15.6.2.1.4. Others
15.6.2.2. Southern Africa Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Cancer Type
15.6.2.2.1. Mast Cell Cancer
15.6.2.2.2. Lymphoma
15.6.2.2.3. Melanoma
15.6.2.2.4. Mammary
15.6.2.2.5. Squamous Cell Cancer
15.6.2.2.6. Others
15.6.2.3. Southern Africa Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Route of Administration
15.6.2.3.1. Oral
15.6.2.3.2. Intravenous
15.6.2.3.3. Others
15.6.2.4. Southern Africa Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Therapy Type
15.6.2.4.1. Chemotherapy
15.6.2.4.2. Targeted Therapy
15.6.2.4.3. Combination Therapy
15.6.2.4.4. Immunotherapy
15.6.3. Rest of MEA
15.6.3.1. Rest of MEA Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Animal Type
15.6.3.1.1. Dogs
15.6.3.1.2. Cats
15.6.3.1.3. Horses
15.6.3.1.4. Others
15.6.3.2. Rest of MEA Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Cancer Type
15.6.3.2.1. Mast Cell Cancer
15.6.3.2.2. Lymphoma
15.6.3.2.3. Melanoma
15.6.3.2.4. Mammary
15.6.3.2.5. Squamous Cell Cancer
15.6.3.2.6. Others
15.6.3.3. Rest of MEA Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Route of Administration
15.6.3.3.1. Oral
15.6.3.3.2. Intravenous
15.6.3.3.3. Others
15.6.3.4. Rest of MEA Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Therapy Type
15.6.3.4.1. Chemotherapy
15.6.3.4.2. Targeted Therapy
15.6.3.4.3. Combination Therapy
15.6.3.4.4. Immunotherapy
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Animal Type
15.7.3. By Cancer Type
15.7.4. By Route of Administration
15.7.5. By Therapy Type
16. Latin America Pet Cancer Therapeutics Market Analysis and
Forecasts, 2019 – 2027
16.1. Overview
16.1.1. Latin America Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units)
16.2. Latin America Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Animal Type
16.2.1. Dogs
16.2.2. Cats
16.2.3. Horses
16.2.4. Others
16.3. Latin America Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Cancer Type
16.3.1. Mast Cell Cancer
16.3.2. Lymphoma
16.3.3. Melanoma
16.3.4. Mammary
16.3.5. Squamous Cell Cancer
16.3.6. Others
16.4. Latin America Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Route of Administration
16.4.1. Oral
16.4.2. Intravenous
16.4.3. Others
16.5. Latin America Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Therapy Type
16.5.1. Chemotherapy
16.5.2. Targeted Therapy
16.5.3. Combination Therapy
16.5.4. Immunotherapy
16.6. Latin America Pet Cancer Therapeutics Market Volume and
Revenue (US$ Mn and Units) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Animal Type
16.6.1.1.1. Dogs
16.6.1.1.2. Cats
16.6.1.1.3. Horses
16.6.1.1.4. Others
16.6.1.2. Brazil Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Cancer Type
16.6.1.2.1. Mast Cell Cancer
16.6.1.2.2. Lymphoma
16.6.1.2.3. Melanoma
16.6.1.2.4. Mammary
16.6.1.2.5. Squamous Cell Cancer
16.6.1.2.6. Others
16.6.1.3. Brazil Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Route of Administration
16.6.1.3.1. Oral
16.6.1.3.2. Intravenous
16.6.1.3.3. Others
16.6.1.4. Brazil Pet Cancer Therapeutics Market Volume and Revenue (US$
Mn and Units) and Forecasts, By Therapy Type
16.6.1.4.1. Chemotherapy
16.6.1.4.2. Targeted Therapy
16.6.1.4.3. Combination Therapy
16.6.1.4.4.
Immunotherapy
16.6.2. Argentina
16.6.2.1. Argentina Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Animal Type
16.6.2.1.1. Dogs
16.6.2.1.2. Cats
16.6.2.1.3. Horses
16.6.2.1.4. Others
16.6.2.2. Argentina Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Cancer Type
16.6.2.2.1. Mast Cell Cancer
16.6.2.2.2. Lymphoma
16.6.2.2.3. Melanoma
16.6.2.2.4. Mammary
16.6.2.2.5. Squamous Cell Cancer
16.6.2.2.6. Others
16.6.2.3. Argentina Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Route of Administration
16.6.2.3.1. Oral
16.6.2.3.2. Intravenous
16.6.2.3.3. Others
16.6.2.4. Argentina Pet Cancer Therapeutics Market Volume and Revenue
(US$ Mn and Units) and Forecasts, By Therapy Type
16.6.2.4.1. Chemotherapy
16.6.2.4.2. Targeted Therapy
16.6.2.4.3. Combination Therapy
16.6.2.4.4. Immunotherapy
16.6.3. Rest of Latin America
16.6.3.1. Rest of Latin America Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units) and Forecasts, By Animal Type
16.6.3.1.1. Dogs
16.6.3.1.2. Cats
16.6.3.1.3. Horses
16.6.3.1.4. Others
16.6.3.2. Rest of Latin America Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units) and Forecasts, By Cancer Type
16.6.3.2.1. Mast Cell Cancer
16.6.3.2.2. Lymphoma
16.6.3.2.3. Melanoma
16.6.3.2.4. Mammary
16.6.3.2.5. Squamous Cell Cancer
16.6.3.2.6. Others
16.6.3.3. Rest of Latin America Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units) and Forecasts, By Route of Administration
16.6.3.3.1. Oral
16.6.3.3.2. Intravenous
16.6.3.3.3. Others
16.6.3.4. Rest of Latin America Pet Cancer Therapeutics Market Volume
and Revenue (US$ Mn and Units) and Forecasts, By Therapy Type
16.6.3.4.1. Chemotherapy
16.6.3.4.2. Targeted Therapy
16.6.3.4.3. Combination Therapy
16.6.3.4.4. Immunotherapy
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Animal Type
16.7.3. By Cancer Type
16.7.4. By Route of Administration
16.7.5. By Therapy Type
17. Competitive Benchmarking
17.1. Market Share Analysis, 2018
17.2. Global Presence and Growth Strategies
17.2.1. Mergers and Acquisitions
17.2.2. Product Launches
17.2.3. Investments Trends
17.2.4. R&D Initiatives
18. Player Profiles
18.1. AdvaVet
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Advaxis Inc.
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Amgen Inc.
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Aratana Therapeutics, Inc.
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Boehringer Ingelheim International GmbH
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. CanFel Therapeutics
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. ELIAS Animal Health
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Fetch Pharma
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Genentech
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Innogenics
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. Karyopharm Therapeutics
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Kindred Biosciences
18.12.1. Company Details
18.12.2. Company Overview
18.12.3. Product Offerings
18.12.4. Key Developments
18.12.5. Financial Analysis
18.12.6. SWOT Analysis
18.12.7. Business Strategies
18.13. Morphogenesis, Inc.
18.13.1. Company Details
18.13.2. Company Overview
18.13.3. Product Offerings
18.13.4. Key Developments
18.13.5. Financial Analysis
18.13.6. SWOT Analysis
18.13.7. Business Strategies
18.14. NIPPON ZENYAKU KOGYO CO., LTD.
18.14.1. Company Details
18.14.2. Company Overview
18.14.3. Product Offerings
18.14.4. Key Developments
18.14.5. Financial Analysis
18.14.6. SWOT Analysis
18.14.7. Business Strategies
18.15. Oasmia Pharmaceutical AB
18.15.1. Company Details
18.15.2. Company Overview
18.15.3. Product Offerings
18.15.4. Key Developments
18.15.5. Financial Analysis
18.15.6. SWOT Analysis
18.15.7. Business Strategies
18.16. PetLife Pharmaceuticals, Inc.
18.16.1. Company Details
18.16.2. Company Overview
18.16.3. Product Offerings
18.16.4. Key Developments
18.16.5. Financial Analysis
18.16.6. SWOT Analysis
18.16.7. Business Strategies
18.17. Pharmaust.
18.17.1. Company Details
18.17.2. Company Overview
18.17.3. Product Offerings
18.17.4. Key Developments
18.17.5. Financial Analysis
18.17.6. SWOT Analysis
18.17.7. Business Strategies
18.18. Phibro Animal Health Corporation
18.18.1. Company Details
18.18.2. Company Overview
18.18.3. Product Offerings
18.18.4. Key Developments
18.18.5. Financial Analysis
18.18.6. SWOT Analysis
18.18.7. Business Strategies
18.19. Regeneus Ltd
18.19.1. Company Details
18.19.2. Company Overview
18.19.3. Product Offerings
18.19.4. Key Developments
18.19.5. Financial Analysis
18.19.6. SWOT Analysis
18.19.7. Business Strategies
18.20. Rhizen Pharmaceuticals S.A.
18.20.1. Company Details
18.20.2. Company Overview
18.20.3. Product Offerings
18.20.4. Key Developments
18.20.5. Financial Analysis
18.20.6. SWOT Analysis
18.20.7. Business Strategies
18.21. Torigen Pharmaceutical Inc.
18.21.1. Company Details
18.21.2. Company Overview
18.21.3. Product Offerings
18.21.4. Key Developments
18.21.5. Financial Analysis
18.21.6. SWOT Analysis
18.21.7. Business Strategies
18.22. Vaccibody
18.22.1. Company Details
18.22.2. Company Overview
18.22.3. Product Offerings
18.22.4. Key Developments
18.22.5. Financial Analysis
18.22.6. SWOT Analysis
18.22.7. Business Strategies
18.23. VetDC
18.23.1. Company Details
18.23.2. Company Overview
18.23.3. Product Offerings
18.23.4. Key Developments
18.23.5. Financial Analysis
18.23.6. SWOT Analysis
18.23.7. Business Strategies
18.24. Virbac.
18.24.1. Company Details
18.24.2. Company Overview
18.24.3. Product Offerings
18.24.4. Key Developments
18.24.5. Financial Analysis
18.24.6. SWOT Analysis
18.24.7. Business Strategies
18.25. Zoetis Services LLC
18.25.1. Company
Details
18.25.2. Company
Overview
18.25.3. Product
Offerings
18.25.4. Key
Developments
18.25.5. Financial
Analysis
18.25.6. SWOT
Analysis
18.25.7. Business Strategies
19.
Key Findings
Note: This ToC is
tentative and can be changed according to the research study conducted during
the course of report completion.
**Exclusive for Multi-User and
Enterprise User
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.